Stock News

The psilocybin developer expects its final application submission within two weeks, with a launch targeted for the first half of 2027.

Genomic analysis volume reached a record 118,000 as the company narrowed its adjusted EBITDA loss and targeted the upper end of annual guidance.

The September-quarter operating loss included a US$6.2M bitcoin-sale gain, while cash and short-term deposits reached US$39.7M.

The maiden program will test soil anomalies in about seven holes, with drilling expected to finish in roughly four weeks.

Adjusted earnings guidance rises to US$2.95 to US$3.05 a share as non-COVID products grow and Pfizer appoints a permanent CFO.

Critical Metals would take an approximately 8 per cent stake, with proceeds supporting expanded Morro do Ferro drilling.

The company confirms federal registrations but does not disclose how many dispensaries received them or identify their locations.

Sensitivity was slightly lower than standard ECGs; a U.S. pivotal study is planned for the first quarter of 2027.

The company allocated US$98.5M of new common-share proceeds to cash while funding preferred buybacks from its general-purpose cash account.

The Alaska result ended in high-grade mineralization and supports further testing of a possible second gold system at Flat.

Lumentum holders would own about 33 per cent of the combined company, with closing expected in the first half of 2028.

The agency cited mouse toxicity and inadequate data for pediatric enrollment; the company is awaiting its full clinical hold letter.

The Saskatchewan uranium explorer plans to test about four target areas, most beneath less than 50 metres of sandstone cover.

The agency set a May 1, 2027 action target for AMT-130 and is tentatively planning an advisory committee meeting.

The Ontario rare-earth and niobium campaign has a C$1.7M budget, alongside an announced one-for-six share consolidation.

The proposed Centalion refinancing carries a nine-month principal holiday and an offtake covering all gold doré produced from the operation.

The Perth team expands BMO’s Australian mining finance business, while Euroz Hartleys retains its independent private wealth operations.

The C$10M facility estimate excludes tenant-owned GPUs, while projected annual rent would be shared with its development partner.

Adjusted earnings beat consensus, but quarterly profit declined and purchase timing boosted pharmaceutical sales by about US$550 million.

The 10 billion yen investment runs through fiscal 2028 and primarily expands manufacturing for the latest LTO Ultrium 10 generation.

A binding MOU includes a conditional share investment and proposed construction debt for an antimony project that has no mineral resource.

Underground drilling returned 18.4 feet at 0.804 per cent tungsten trioxide as surface assays outlined the 360 portal vein in Idaho.

The proposed New York trust bank would provide digital asset custody, trading, staking and fiduciary investment advisory services if approved.

The Peru mine remains in pre-commissioning, with full mill capacity targeted for mid-2027 and a revised mine plan due at year-end.

Quarterly sales rose 39 per cent as Mounjaro and Zepbound demand outweighed price declines, while acquisition charges weighed on earnings.

Opzelura and hematology sales drove the forecast increase, while a US$1.23 billion acquisition charge lifted research expense.

The California silver project has an estimated US$737 million after-tax net present value using a US$55-an-ounce price assumption.

The Ethiopian mine targets 25,000 to 35,000 ounces in November and December, with commercial production expected in the same period.

The brewer has cut its U.S. footprint to six facilities, while keeping fiscal 2027 adjusted earnings guidance unchanged.

CME futures favour a December increase after a divided vote keeps the benchmark range at 3.75 to 4 per cent.

The six-lender transaction returns capital from deployed servers, but the release gives no interest rate, maturity or repayment schedule.

NexaCore gets a 24-month study window, while land terms, capacity and financing remain subject to further work.

The combination beat pembrolizumab alone on survival and tumour response in first-line PD-L1-positive head-and-neck cancer.

The bank expects energy prices to rise 32 per cent in 2026, while independent EIA forecasts put oil costs above its baseline.

The magnet maker targets roughly 10,000 tonnes of annual capacity after commissioning and has scheduled a Dec. 17 operational showcase.

All eight Cruzeta holes ended in mineralization, but Spark has yet to demonstrate recovery or establish a mineral resource at Arapaima.

The application draws on 168 participants, including a preliminary randomized trial using a significance threshold of 0.2.

QTORIN rapamycin could become the first approved treatment for microcystic lymphatic malformations, with a potential U.S. launch in early 2027.

Previously announced economics assume US$25,000 a tonne lithium carbonate and estimate a 10.8 per cent after-tax return.

Six holes test extensions at Airstrip, including mineralization down-dip toward Powerline near the conceptual pit boundary.